Gastric Diffuse Large B-Cell Lymphoma: A Single-Center 9-Year Experience
| Autor: | Rui Henrique, Ana Espirito-Santo, Isabel Oliveira, Ângelo Martins, Sérgio Chacim, Maria Eduarda Couto, Nelson Luís de Campos Domingues, Dulcineia Pereira, Cláudia Moreira, Jose Mario Mariz, Luisa Viterbo, Ilídia Moreira |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Aggressive
medicine.medical_specialty Short Communication Population 030204 cardiovascular system & hematology Single Center Gastroenterology 03 medical and health sciences 0302 clinical medicine Gastric Internal medicine medicine Progression-free survival education education.field_of_study Hematology business.industry Gastric Diffuse Large B-Cell Lymphoma medicine.disease Non-Hodgkin's lymphoma B symptoms Non-Hodgkin’s lymphoma Rituximab medicine.symptom business 030215 immunology medicine.drug |
| Zdroj: | Indian Journal of Hematology & Blood Transfusion |
| ISSN: | 0974-0449 0971-4502 |
| DOI: | 10.1007/s12288-020-01391-9 |
| Popis: | Gastric diffuse large B cell lymphoma (DLBCL) represents the majority of all gastric lymphomas. We report a series of gastric DLBCL diagnosed and treated in a single center, between 2010 and 2018 (included). We retrospectively analyzed the population demographic features, treatment outcomes and survival. One-hundred-and-one patients were studied, 50.5% males and median age of 64 years [23–94]. Lugano staging was I in 16.8%, II1 in 20.8%, II2 in 10.9%, IIE in 13.9% and IV in 34.7% of cases. Twenty percent had Helicobacter pylori infection. R-CHOP-like therapy was used as first line in 96.9% of the patients. A complete response was achieved in 80% after first line therapy. At 3-years of follow-up (FU), 54% were in complete remission. The mean FU time was 73.6 months. Median overall survival and median progression free survival were not reached. We identified seven factors with negative impact in survival: age above 65 years-old (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink